Tak Cheung
SlowingNamed in filings at Astoria Health InvestorsOn the current fund
- Board seats filed
- 5
Named in filings at Astoria Health InvestorsOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Cagent Vascular | Medical devices | May 2026 | U.S Venture Partners |
| X9 | Medical devices | November 2022 | NEA |
| SpyGlass Ophthalmics | Biotech & pharma | December 2020 | Vensana Capital, Versant Venture Capital |
| Allay Therapeutics | Biotech & pharma | January 2019 | Arboretum Ventures, Baird Venture Partners, Domain Partners |
| Eargo | Medical devices | December 2018 | Maveron, NEA, Pivotal bioVenture Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Tak Cheung on the board, based on 5 filed seats with a verified or cited source.